Free Newsletter
Ruling could remodel whistleblower world
Free newsletter via e-mail
Tools
A federal appeals court has ruled that Cell Therapeutics can pursue a claim for nearly $23 million against a former consultant that advised it to market a drug off-label, adding a whole new wrinkle to whistleblower lawsuits. Report
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact
